Exploration of Treatment-Associated Biomarkers and Development of an Efficacy Prediction System for p53-armed Oncolytic Viruses

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20942
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0905:Surgery of the organs maintaining homeostasis and related fields
• Research Institution: Okayama University
• Principal Investigator: Kadowaki Daisuke 岡山大学, 大学病院, 医員 (30966255)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: Oncolytic Virus / がんウイルス療法 / OBP-702 / 腫瘍融解ウイルス / バイオマーカ― / OBP-301 / p53

Outline of Final Research Achievements

In this study, we validated the cytotoxic activity of OBP-702, OBP-301, and Ad-p53 against various cancer cell lines. We calculated the 50% inhibitory concentration and conducted comprehensive analyses based on this data to search for biomarkers of OBP-702. We divided the anti-tumor mechanism of OBP-702 into elements such as "viral infection," "viral replication," and "p53," and examined factors such as "CAR," "Ki67," and "p53 gene mutations" that were associated with the anti-tumor effect of OBP-702. We regarded these three factors as biomarkers and constructed a scoring system to predict the therapeutic effect of OBP-702, confirming its correlation with the therapeutic effect in vitro.

Free Research Field

Oncolytic Virus

Academic Significance and Societal Importance of the Research Achievements

がんウイルス療法は高い腫瘍特異性を有し、既存の治療法とは異なるメカニズムで 細胞死を誘導する新規治療法のひとつである。現段階では、がんウイルス療法における普遍的な、あるいは個々のウイルス治療薬に特異的なバイオマーカーの報告はなく、独自のバイオマーカー探索が必要と考えられる。本研究では、約50種のヒトがん細胞株を使用して、OBP-702（p53搭載腫瘍融解アデノウイルス)の治療関連バイオマーカーの同定を行い、その効果予測システムの構築を行った。